Navigation Links
Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
Date:10/10/2011

ype="disc">
  • PSI-7977 400 mg monotherapy for 12 weeks (n=25 GT1 treatment-naive)
  • PSI-7977 400 mg with RBV for 12 weeks (n=25 GT2/3 treatment-experienced)

  • About Pharmasset

    Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates advancing in trials in various populations. Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in five Phase 2b trials, including abbreviated duration interferon and interferon-free regimens, in subjects with all HCV genotypes. Our purine, PSI-938, an unpartnered guanosine nucleotide analog, is in QUANTUM, a Phase 2b interferon-free trial of PSI-7977 and PSI-938 in subjects with all HCV genotypes. Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    Office: +1 (609) 865-0693

    Forward-Looking Statements

    Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted stud
    '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Pharmasset to Present at Two Upcoming Conferences
    2. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
    3. Pharmasset Announces Two-for-One Forward Stock Split
    4. Pharmasset to Present at Canaccord Genuity Growth Conference
    5. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
    6. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
    7. Pharmasset to Present at Two Upcoming Investor Conferences
    8. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
    9. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
    10. Pharmasset to Webcast an Investor Event From the EASL Meeting
    11. Pharmasset to Present at Three Upcoming Investor Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/30/2015)... -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces the ... StockholdersWhen:Tuesday, June 30 at 5:10 p.m. ET / 2:10 ... onto our website listed above.   If ... a replay of the webcast will be available for ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting ...
    (Date:6/29/2015)... 30, 2015 , Gerresheimer will sell ... and Gerresheimer enter into a 10-year-supply agreement for pharmaceutical ... EUR 196m debt-free Corning and Gerresheimer will ... glass packaging market Gerresheimer,s outlook for the financial ... disposal of the tubing business , In line ...
    (Date:6/29/2015)... 29, 2015  Nevro Corp. (NYSE: NVRO ), ... evidence-based solutions for the treatment of chronic pain, today ... Executive Officer of Intersect ENT (NASDAQ: XENT ), ... June 28, 2015. For the last ... Intersect ENT, a company dedicated to improving the quality ...
    Breaking Medicine Technology:Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 2Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 3Gerresheimer Will Sell Tubing Operations to Corning - Both Will Form a Joint Venture to Accelerate Innovations for Pharmaceutical Glass Packaging Market 2Gerresheimer Will Sell Tubing Operations to Corning - Both Will Form a Joint Venture to Accelerate Innovations for Pharmaceutical Glass Packaging Market 3Nevro Appoints Lisa Earnhardt to its Board of Directors 2
    ... HAIFA, Israel, November 11 Cardio Vascular,Medical ... advanced,cardiovascular surgery technology, today announced the completion of ... . , Cardio Vascular ... innovative,next-generation "steerable guidewire" applicable for all angioplasty (PCTA),procedures. ...
    ... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin ... commercial launch of MuGard, an FDA approved treatment for oral ... Access intends to commercially launch MuGard in North America ... pertaining to the launch include: , Manufacturing : ...
    Cached Medicine Technology:Cardio Vascular Medical Device Launches Corporate Website 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America 4
    (Date:6/30/2015)... ... June 30, 2015 , ... The Citizens Commission ... Davis (D-IL) for writing to the Department of Health and Human Services (HHS), ... healthcare system, Universal Health Services (UHS).[1] CCHR is expanding its seven-year review of ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Nuretix Research, creators of ... Zone Miami (KO Zone), a state-of-the-art training facility owned by leading ... de Vera. The partnership will provide KO Zone clients and athletes with Liporidex ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Under ... protection at less thickness than any other padding in football. , Developed in ... and shock absorption, Gameday Armour is engineered with D3O protective polymer. This radical ...
    (Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up to ... Back pain can range from a dull, constant ache (chronic) to a sudden sharp ... epidural steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain & ...
    (Date:6/30/2015)... ... 30, 2015 , ... People who want to learn more ... a near-death experience (NDE) – and also want to understand why the military ... – are invited to visit https://zoom.us/webinar/register/f4a12556fe7c03f5dc2040ba88984b7b and RSVP their attendance at ...
    Breaking Medicine News(10 mins):Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 2Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 3Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 4Health News:CCHR Seeks Public Input on Psychotropic Drug Billing and Psychiatric Abuse: Applauds Congressmen for Behavioral Hospitals Investigation Call 5Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 2Health News:Top Sports Nutrition Brand, Liporidex, Announces Partnership With Leading Boxing, CrossFit and MMA Gym, Knockout Zone of Miami 3Health News:Under Armour Launches Advanced Gameday Armour® Max Protection System For The Gridiron 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:IANDS Sponsors No-Cost Webinar on July 1/15 at 11CST Featuring Combat Soldier Who Survived Near-Death Experience 2Health News:IANDS Sponsors No-Cost Webinar on July 1/15 at 11CST Featuring Combat Soldier Who Survived Near-Death Experience 3
    ... Assia, of Tel Aviv Universitys Sackler School of Medicine is, ... surgery. , One of a small number of surgeons in ... surgery, Prof. Assia has developed a novel laser device that ... the OTS134 for now, is expected to give most practicing ...
    ... Sept. 14, 2007 -- A new study by researchers at ... be good for you. , Researchers found that a ... with teen obesity, hypertension and healthy eating habits had a ... among men. , The study, published in the Sept. 14 ...
    ... department reported that their anxiety levels fell dramatically when they ... research in the September issue of the UK-based Journal of ... provided over the course of a year. 86 nurses participated ... summer and winter sessions. , Researchers found that 60 ...
    ... kill off cancer cells, experts say , FRIDAY, Sept. ... called unplanned cell death, or necrosis, could help in ... life-threatening conditions, scientists say. , Necrosis is not the ... Necrosis is an unplanned cell death caused by outside ...
    ... offers possible advance over invasive tests , , FRIDAY, Sept. ... a mother-to-be,s blood could become the lens through which ... a new study suggests. , "It,s amazing that all ... in their blood," said Dr. Jill L. Maron, the ...
    ... N.J., Sept. 21 Schering-Plough,Corporation (NYSE: SGP ) ... the 2007 third quarter on Monday, Oct. 22, 2007. ... will conduct a conference,call to review results for the ... other members of management will,host the conference call. ...
    Cached Medicine News:Health News:Glaucoma surgery in the blink of an eye 2Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels 2Health News:Giving emergency nurses aromatherapy massages with music dramatically reduced stress levels 3Health News:Clues to Cell Death Could Fight Disease 2Health News:Mother's Blood Could Offer Insights Into Fetal Health 2Health News:Mother's Blood Could Offer Insights Into Fetal Health 3
    Shandon Microscope Slide Cabinet with Drawers...
    ... data from multiple sources is not ... ResultNet/Plus software allows you to concentrate ... communications network., ,ResultNet/Plus eliminates the complexity ... largescale or multi-site laboratories to host ...
    The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
    ACE Control Serum provides the laboratory with vital information on the performance of the ACE chemistry assay....
    Medicine Products: